AS1266 / Ascentage Pharma - LARVOL DELTA

Bioinformatic analysis and validation of microRNA-508-3p as a protective predictor by targeting NR4A3/MEK axis in pulmonary arterial hypertension. (PubMed, J Cell Mol Med) - "In this study, 185 DEGs and three common DEMs were screened as well as 1266 target genes of the three DEMs were identified...Mechanistically, we demonstrated that down-regulation of miR-508-3p advances PASMC proliferation and migration via inducing NR4A3 to activate MAPK/ERK kinase signalling pathway. Altogether, our research provides a promising diagnosis of predictor and therapeutic avenues for patients in PAH."

Journal • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • MIR508 • NR4A3